Ardsley Advisory Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

Ardsley Advisory Partners’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-3,000	Closed	-$370K	–	149
2020 Q2	$370K	Buy	+3,000	New	+$298K	0.08%	94
2018 Q2	–	Sell	-10,000	Closed	-$811K	–	157
2018 Q1	$811K	Hold	10,000	–	–	0.12%	73
2017 Q4	$892K	Buy	10,000 +3,000	+43%	+$261K	0.11%	78
2017 Q3	$651K	Hold	7,000	–	–	0.09%	89
2017 Q2	$636K	Sell	7,000 -82,500	-92%	-$7.51M	0.1%	87
2017 Q1	$7.86M	Buy	+89,500	New	+$7.96M	1.22%	29
2016 Q4	–	Sell	-2,500	Closed	-$231K	–	136
2016 Q3	$231K	Buy	+2,500	New	+$235K	0.04%	132
2016 Q1	–	Sell	-2,500	Closed	-$262K	–	149
2015 Q4	$262K	Buy	+2,500	New	+$261K	0.03%	115

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ardsley Advisory Partners's BMRN Position: Q3 2020 in Review

Ardsley Advisory Partners sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2020, closing a stake of 3,000 shares — an estimated $370K sold.

Ardsley Advisory Partners first reported a position in BMRN in Q4 2015 and held it in 8 quarters. The position peaked at $7.86M in Q1 2017. 497 funds tracked by Wall St. Rank hold BMRN as of Q3 2020.

Ardsley Advisory Partners reported no remaining BioMarin Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Ardsley Advisory Partners sold 3,000 BioMarin Pharmaceuticals shares in Q3 2020, an estimated $370K.
Ardsley Advisory Partners first reported a position in BioMarin Pharmaceuticals in Q4 2015 and held it in 8 quarters.
Ardsley Advisory Partners's BioMarin Pharmaceuticals position peaked at $7.86M in Q1 2017.
497 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2020.

Based on Ardsley Advisory Partners's 13F filing for Q3 2020, filed 13 Nov 2020.